<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664647</url>
  </required_header>
  <id_info>
    <org_study_id>haojunwei1</org_study_id>
    <nct_id>NCT04664647</nct_id>
  </id_info>
  <brief_title>The Clinical Features of Combined Central and Peripheral Demyelination</brief_title>
  <acronym>CCPD</acronym>
  <official_title>The Clinical Features of Combined Central and Peripheral Demyelination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct this study to clarify the clinical features and to evaluate the&#xD;
      prevalence of anti-nodal/paranodal antibodies of patients with combined central and&#xD;
      peripheral demyelination (CCPD) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will review the clinical manifestation, laboratory test results,&#xD;
      electrophysiological examination and neuroimaging findings of patients with CCPD. And we will&#xD;
      detect antibodies to aquaporin 4(AQP4), myelin oligodendrocyte glycoprotein (MOG),&#xD;
      neurofascin-155 (Nfasc155), neurofascin-186 (Nfasc186), and myelin-associated glycoprotein&#xD;
      (MAG) in patients with CCPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory findings of nodal/paranodal antibodies in blood of patients with CCPD</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>These antibody including anti-neurofascin 155(NF155) et.al.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>The demographic characteristics of patients with CCPD such as age,sex,and et.al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological symptoms and signs</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>The neurological symptoms and signs of patients with CCPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory findings of blood and cerebrospinal fluid</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>Laboratory findings of blood and cerebrospinal fluid of patients with CCPD such as C reactive protein et.al in blood and protein et.al in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging and VEPs findings</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>Neuroimaging and VEPs findings of patients with CCPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve conduction study findings</measure>
    <time_frame>Day 1 post-gathering information of patients in hospital medical record system</time_frame>
    <description>Nerve conduction study findings of patients with CCPD</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Combined Central and Peripheral Demyelination Disease</condition>
  <arm_group>
    <arm_group_label>Patients with CCPD</arm_group_label>
    <description>Inclusion criteria：&#xD;
Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.&#xD;
Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.&#xD;
Exclusion criterion:&#xD;
Secondary demyelinating diseases or changes.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have combined central and peripheral demyelination&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. T2 high-signal intensity lesions in the brain or spinal cord on MRI, or visual-evoked&#xD;
             potentials(VEPs) abnormalities.&#xD;
&#xD;
          2. conduction delay, conduction block, temporal dispersion or F-wave abnormalities,&#xD;
             suggesting peripheral demyelinating neuropathy regarding nerve conduction studies&#xD;
             (NCS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. infectious diseases(e.g., human T lymphocyte trophic virus type1-associated&#xD;
             myelopathy, syphilis, neuroborreliosis, HIV infection or progressive multifocal&#xD;
             leukoencephalopathy)&#xD;
&#xD;
          2. pre-existing inflammatory diseases (e.g., sarcoidosis, Behçet's disease, Sjögren's&#xD;
             syndrome, vasculitis or other collagen diseases)&#xD;
&#xD;
          3. mitochondrial disease&#xD;
&#xD;
          4. metabolic/toxic diseases (e.g., vitamin deficiency, amyloidosis, chronic alcoholism,&#xD;
             diabetes mellitus or subacute myelo-opticoneuropathy due to clioquinol intoxication&#xD;
&#xD;
          5. cervical spondylotic myelopathy&#xD;
&#xD;
          6. syringomyelia&#xD;
&#xD;
          7. spinocerebellar degeneration&#xD;
&#xD;
          8. multiple myeloma, other tumors&#xD;
&#xD;
          9. inherited diseases (e.g., leucodystrophies)&#xD;
&#xD;
         10. cerebrovascular disease&#xD;
&#xD;
         11. non-specific lesions on T2-weighted MRI (e.g., leucoaraiosis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junwei Hao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junwei Hao, MD,PhD</last_name>
    <phone>010-83199088</phone>
    <email>haojunwei@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaodan Hou, MD</last_name>
    <phone>+8618935415649</phone>
    <email>hxddoc@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cortese A, Franciotta D, Alfonsi E, Visigalli N, Zardini E, Diamanti L, Prunetti P, Osera C, Gastaldi M, Berzero G, Pichiecchio A, Piccolo G, Lozza A, Piscosquito G, Salsano E, Ceroni M, Moglia A, Bono G, Pareyson D, Marchioni E. Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment. J Neurol Sci. 2016 Apr 15;363:182-7. doi: 10.1016/j.jns.2016.02.022. Epub 2016 Feb 10.</citation>
    <PMID>27000248</PMID>
  </reference>
  <reference>
    <citation>Ogata H, Matsuse D, Yamasaki R, Kawamura N, Matsushita T, Yonekawa T, Hirotani M, Murai H, Kira J. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):29-36. doi: 10.1136/jnnp-2014-309831. Epub 2015 Feb 11.</citation>
    <PMID>25673872</PMID>
  </reference>
  <reference>
    <citation>Wang YQ, Chen H, Zhuang WP, Li HL. The clinical features of combined central and peripheral demyelination in Chinese patients. J Neuroimmunol. 2018 Apr 15;317:32-36. doi: 10.1016/j.jneuroim.2018.02.006. Epub 2018 Feb 9.</citation>
    <PMID>29501083</PMID>
  </reference>
  <reference>
    <citation>Nave KA, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503-33. doi: 10.1146/annurev-cellbio-100913-013101. Review.</citation>
    <PMID>25288117</PMID>
  </reference>
  <reference>
    <citation>Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 2015 Mar;11(3):143-56. doi: 10.1038/nrneurol.2014.260. Epub 2015 Jan 27. Review.</citation>
    <PMID>25623793</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>haojunwei</investigator_full_name>
    <investigator_title>Princple investigation</investigator_title>
  </responsible_party>
  <keyword>CCPD</keyword>
  <keyword>clinical features</keyword>
  <keyword>antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Demyelinating Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

